METHODS: A total of 138 breast cancer specimens were examined on an immunohistochemical basis. A statistical analysis was performed in order to examine the association between HDAC-2 and the survival and clinicopathological features of the patients.
RESULTS: Increased HDAC-2 expression was observed in every fourth case of triple negative breast cancer with positive HDAC-2 staining, whereas only 12 out of 98 non-triple negative breast cancer samples showed high HDAC-2 expression. HDAC-2 overexpression correlated with prolonged overall survival (OS) and disease-free survival (DFS) in triple negative breast cancer.
CONCLUSIONS: High HDAC-2 levels in triple negative breast cancer seem to positively influence patient survival, disease stage and recurrence.
方法:对138例乳腺癌标本进行免疫组织化学检查。进行统计分析以检查HDAC-2与患者的生存和临床病理特征之间的关联。
结果:在每4例HDAC-2染色阳性的三阴性乳腺癌中观察到HDAC-2表达增加,而98例非三阴性乳腺癌样本中只有12例显示高HDAC-2表达.HDAC-2过表达与三阴性乳腺癌的总生存期(OS)和无病生存期(DFS)延长相关。
结论:三阴性乳腺癌中的高HDAC-2水平似乎对患者的生存率有积极影响。疾病阶段和复发。